Diabetes

We recommend

How Does Empagliflozin Stand in Terms of Diabetic Retinopathy Risk? We Have Answers Not Only from Controlled Studies but Also from Real Practice

5. 12. 2023 Source: Diabetes

Modern antidiabetics –⁠ gliflozins and glucagon-like peptide-1 receptor agonists (GLP-1RA) –⁠ significantly help improve the management of type 2 diabetes (DM2). In addition to reliable glycemic control, they offer other benefits. For example, gliflozins are known for their cardio -⁠ and renoprotective properties. GLP-1RA also reduce cardiovascular (CV) risk, though clinical evaluation (SUSTAIN-6) suggests a possible higher risk of retinopathy. This is also being investigated with gliflozins. How empagliflozin fares in this respect has been…

The Significance of Administering Gliflozins in Real Practice in Diabetics Without CV and Renal Disease

Current care standards recommend the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i,…

5. 12. 2023 Source: Diabetes

Benefit of Empagliflozin in Patients with Chronic Kidney Disease –⁠ Results of the EMPA-KIDNEY Study

The sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin is currently used to treat type…

18. 10. 2023 Source: Diabetes

Articles on this topic

E-courses on this topic

Authors: Prof. MUDr. Martin Haluzík, DrSc., prof. MUDr. Vojtěch Melenovský, CSc., prof. MUDr. Vladimír Tesař, DrSc.

Course detail

Diabetes

How Does Empagliflozin Stand in Terms of Diabetic Retinopathy Risk? We Have Answers Not Only from Controlled Studies but Also from Real Practice

The Significance of Administering Gliflozins in Real Practice in Diabetics Without CV and Renal Disease

Benefit of Empagliflozin in Patients with Chronic Kidney Disease –⁠ Results of the EMPA-KIDNEY Study

Cardiovascular Benefit of SGLT2 Inhibitors Confirmed

Impact of Oral Antidiabetics on Heart Failure

Journal articles Type 1 and 2 diabetes and pregnancy

Journal articles Type 2 diabetes mellitus in old age